Cancer cell senescence: a new frontier in drug development

Cairney, C.J., Bilsland, A.E., Evans, T.R.J. , Roffey, J., Bennett, D.C., Narita, M., Torrance, C. and Keith, W.N. (2012) Cancer cell senescence: a new frontier in drug development. Drug Discovery Today, 17(5-6), pp. 269-276. (doi:10.1016/j.drudis.2012.01.019)

Full text not currently available from Enlighten.

Abstract

Senescence forms a universal block to tumorigenesis which impacts on all hallmarks of cancer, making it an attractive target for drug discovery. Therefore a strategy must be devised to focus this broad potential into a manageable drug discovery programme. Several issues remain to be addressed including the lack of robust senescence-inducing compounds and causally related biomarkers to measure cellular response. Here, we review the latest progress in translating senescence as a target for cancer therapy and some promising approaches to drug and biomarker discovery. Finally, we discuss the potential application of a senescence-induction therapy in a clinical setting.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Bilsland, Dr Alan and Evans, Professor Thomas and Cairney, Dr Claire and Keith, Professor Nicol
Authors: Cairney, C.J., Bilsland, A.E., Evans, T.R.J., Roffey, J., Bennett, D.C., Narita, M., Torrance, C., and Keith, W.N.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing > Clinical Specialities
Journal Name:Drug Discovery Today
ISSN:1359-6446
Published Online:31 January 2012

University Staff: Request a correction | Enlighten Editors: Update this record